Curiel D T, Buchhagen D L, Chiba I, D'Amico D, Takahashi T, Minna J D
NCI-Navy Medical Oncology Branch, Division of Cancer Treatment, Bethesda, Maryland 20814.
Am J Respir Cell Mol Biol. 1990 Nov;3(5):405-11. doi: 10.1165/ajrcmb/3.5.405.
Point mutations in genes can be etiologic of pulmonary diseases, as in the case of the inherited disorders alpha-1-antitrypsin deficiency and cystic fibrosis or in the context of dominant and recessive oncogenes in lung cancer. Various methodologies have been developed to screen for single-base mutations. These techniques include direct DNA sequencing, RNase protection, denaturing gradient gel electrophoresis, and chemical mismatch cleavage. The latter method offers the advantages of rapid and efficient analysis of genomic or cDNA and is thus ideally suited to screening applications. Furthermore, all possible single-base changes can theoretically be detected. In the present work, chemical mismatch cleavage was utilized to detect mutations in the p53 gene in small cell and non-small cell lung cancer. This technique was modified by using a two-step, hemi-nested PCR procedure for preparation of target genomic DNAs permitting an expanded target size for analysis. Evaluation by chemical mismatch cleavage of eight p53 cDNAs derived from lung tumors shown to have different mutations by DNA sequencing correctly detected the presence of a point mutation in all instances. Analysis of six additional tumor genomic DNAs with defined mutations in the corresponding p53 cDNAs accurately confirmed the mutation at the level of the genome. The technique also identified codon 72 and intron 6 polymorphisms. Using the intron 6 polymorphism, loss of heterozygosity at the p53 locus in tumor DNA was readily detected by chemical mismatch cleavage. Finally, utilizing this technique for scanning analysis of the p53 gene of uncharacterized lung tumor DNAs, additional mutations were identified in a prospective manner which were confirmed by sequence analysis.(ABSTRACT TRUNCATED AT 250 WORDS)
基因中的点突变可能是肺部疾病的病因,如遗传性疾病α-1-抗胰蛋白酶缺乏症和囊性纤维化,或肺癌中显性和隐性癌基因的情况。已经开发了各种方法来筛选单碱基突变。这些技术包括直接DNA测序、核糖核酸酶保护、变性梯度凝胶电泳和化学错配切割。后一种方法具有快速高效分析基因组或cDNA的优点,因此非常适合筛选应用。此外,理论上可以检测到所有可能的单碱基变化。在本研究中,利用化学错配切割检测小细胞肺癌和非小细胞肺癌中p53基因的突变。通过使用两步半巢式PCR程序制备靶基因组DNA对该技术进行了改进,从而扩大了分析的靶标大小。通过化学错配切割对8个来自肺肿瘤的p53 cDNA进行评估,这些cDNA经DNA测序显示有不同突变,在所有情况下都正确检测到了点突变的存在。对另外6个在相应p53 cDNA中有明确突变的肿瘤基因组DNA进行分析,准确地在基因组水平上证实了突变。该技术还鉴定了密码子72和内含子6多态性。利用内含子6多态性,通过化学错配切割很容易检测到肿瘤DNA中p53基因座的杂合性缺失。最后,利用该技术对未鉴定的肺肿瘤DNA的p53基因进行扫描分析,前瞻性地鉴定出其他突变,并通过序列分析得到证实。(摘要截短至250字)